Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Stocktwits on MSN
Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale
Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...
Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.’s NVAX COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results